Latest studies
- Active not recruitingPHASE3
A Long-term Extension Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease
This study is looking into the long-term effects and safety of a medicine called mirikizumab for people with Crohn's disease. Participants have already taken part in a related study, and this new study will help us understand how the medicine works over a longer period.
Crohn's DiseaseUkraine - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)
This study is testing a new medication called Tulisokibart for people with moderate to severe Crohn's disease. Researchers want to see if it's safe and effective in reducing symptoms and improving the gut lining. It involves different ways of giving the medicine compared to a dummy treatment.
Crohn's DiseaseUkraine - Active not recruitingPHASE3
A Study of the Efficacy and Safety of Risankizumab in Participants With Crohn's Disease
This study looks at a new medicine called risankizumab for Crohn's disease. We're checking how well it works and if it's safe for people who have already started treatment. It's like a follow-up to see how different doses work and how people feel over time.
Crohn's DiseaseUkraine - Active not recruitingPHASE2, PHASE3
A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
This study looks at a new medicine called guselkumab for adults with moderately to severely active Crohn's disease. Researchers want to see how well it works and if it's safe compared to other treatments or a dummy medicine.
Crohn's DiseaseUkraine - Active not recruitingPHASE3
Study Comparing Intravenous (IV)/Subcutaneous (SC) Risankizumab to IV/SC Ustekinumab to Assess Change in Crohn's Disease Activity Index (CDAI) in Adult Participants With Moderate to Severe Crohn's Disease (CD)
This study compares two treatments, risankizumab and ustekinumab, for adults with moderate to severe Crohn's disease. Researchers want to see which treatment works best to reduce Crohn's symptoms. Both treatments are given initially by IV, then by injection.
Crohn's Disease (CD)Ukraine - Active not recruitingPHASE3
A Maintenance and Long-Term Extension Study of the Efficacy and Safety of Upadacitinib (ABT-494) in Participants With Crohn's Disease Who Completed the Studies M14-431 or M14-433
This study looks at a new medicine called upadacitinib for adults with Crohn's disease. It checks how well it works and if it's safe over a long time for people who have already started treatment in previous studies. The aim is to see if it can help manage Crohn's.
Crohn's DiseaseUkraine - Active not recruitingPHASE3
A Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Adults With Rheumatoid Arthritis Who Are on a Stable Dose of Methotrexate and Who Have an Inadequate Response to Methotrexate
This study compares a new medicine, upadacitinib, with a sugar pill (placebo) and an existing medicine, adalimumab, for adults with rheumatoid arthritis. It looks at how well these treatments work and if they are safe when methotrexate isn't enough on its own.
Rheumatoid ArthritisUkraine - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)
This study looks at the long-term effects and safety of a drug called mirikizumab for people with moderate to severe ulcerative colitis. It can last up to three years, with a chance to continue treatment afterward.
Ulcerative ColitisUkraine - Active not recruitingPHASE3
Phase III Study in First-line Treatment of Patients With Metastatic Colorectal Cancer Who Are Not Candidate for Intensive Therapy.
This study is testing a new combination treatment for advanced bowel cancer. It compares a new medicine (S95005) with an existing one (capecitabine), both given with bevacizumab. The aim is to see if the new combination works better for patients who can't have intensive chemotherapy.
Metastatic Colorectal CancerUkraine - Active not recruitingPHASE3
Savolitinib Plus Durvalumab Versus Sunitinib and Durvalumab Monotherapy in MET-Driven, Unresectable and Locally Advanced or Metastatic PRCC
This study is testing new drug combinations for a type of kidney cancer called Papillary Renal Cell Carcinoma (PRCC). It compares a mix of savolitinib and durvalumab, or just durvalumab, against a standard treatment, sunitinib, for advanced PRCC linked to a specific genetic change.
Papillary Renal Cell CarcinomaUkraine - RecruitingPHASE3
Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects With Psychosis Associated With Alzheimer's Disease (ADEPT-3)
This study looks at the long-term safety of a new medicine, KarXT, for people with changes in their thoughts and feelings due to Alzheimer's disease. Participants have already taken part in similar studies and will continue to be monitored for about a year.
Psychosis Associated With Alzheimer's DiseaseUkraine - Active not recruitingPHASE3
A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for the Treatment of Participants With Deleterious Germline or Somatic Homologous Recombination Repair (HRR) Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
This study is looking at a new treatment for men with prostate cancer that has spread and is responding to hormone therapy. It combines a drug called niraparib with standard treatments (abiraterone acetate and prednisone) to see if it works better for those with specific genetic changes.
Metastatic Castration-sensitive Prostate CancerUkraine - Active not recruitingPHASE3
A Study Evaluating the Efficacy and Safety of Giredestrant Combined With Palbociclib Compared With Letrozole Combined With Palbociclib in Participants With Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer (persevERA Breast Cancer)
This study is testing a new combination of medicines, Giredestrant and Palbociclib, for advanced breast cancer. It's for people whose cancer is hormone-sensitive (ER-positive) but not HER2-positive. Researchers want to see if this new combination works better and is safer than a standard treatment.
Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast CancerUkraine - Active not recruitingPHASE3
Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPC
This study looks at a new combination of drugs, cabozantinib and atezolizumab, for men with prostate cancer that has spread and is no longer responding to hormone therapy. It compares this new combination with standard hormone treatments to see if it works better.
Metastatic Prostate CancerProstate AdenocarcinomaUkraine - Active not recruitingPHASE2
A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study
This study is for men with prostate cancer who are already taking enzalutamide as part of another research study. It aims to gather more information on the long-term safety of enzalutamide when it's helping them. Participants will continue their current treatment and have regular check-ups.
Prostate CancerUkraine - Enrolling by invitationPHASE3
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
This study looks at the long-term effects and safety of a drug called Ralinepag for people with a lung condition called pulmonary arterial hypertension (PAH). It's for those who have already tried Ralinepag in a previous study.
PAHPulmonary HypertensionPulmonary Arterial HypertensionHypertensionUkraine - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent (MK-3475-B21 / KEYNOTE-B21 / ENGOT-en11 / GOG-3053)
This study looks at a new drug, pembrolizumab, combined with standard chemotherapy after surgery for certain types of womb cancer (endometrial cancer). We want to see if this combination helps stop the cancer from coming back and helps people live longer compared to chemotherapy alone.
Endometrial NeoplasmsUkraine - RecruitingPHASE3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease
This study is looking into a new treatment called KarXT + KarX-EC for agitation (feeling restless or upset) in people with Alzheimer's disease. It wants to see if the treatment is safe and if it helps reduce agitation.
Alzheimer's DiseaseUkraine - Active not recruitingPHASE3
Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
This study compares a new drug combination (enfortumab vedotin plus pembrolizumab) with standard chemotherapy for bladder cancer that has spread to the muscle. It aims to see if the new combination, given before surgery, works better and is safe.
Bladder CancerUkraine - Active not recruitingPHASE2, PHASE3
A Study of Guselkumab in Participants With Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called guselkumab for people with ulcerative colitis that isn't well-controlled. We want to see if it helps reduce symptoms and if it's safe to use for those with moderate to severe forms of the condition.
Ulcerative ColitisUkraine - Active not recruitingPHASE3
A Study to Investigate Long-term Safety and Tolerability of Tolebrutinib in Participants With Multiple Sclerosis.
This study looks at the everyday safety and how well a drug called tolebrutinib is tolerated over a long time. It's for adults with different types of multiple sclerosis (MS) who have already been in earlier tolebrutinib studies.
Relapsing Multiple SclerosisSecondary Progressive Multiple SclerosisProgressive Relapsing Multiple SclerosisUkraine - RecruitingPHASE3
A Study of Baricitinib (LY3009104) to Preserve Beta Cell Function in Children and Adults Newly Diagnosed With Type 1 Diabetes (BARICADE-PRESERVE)
This study investigates if a drug called baricitinib can protect the body's insulin-making cells in children and adults newly diagnosed with type 1 diabetes. It aims to see if preserving these cells helps manage the condition better.
Diabetes Mellitus, Type 1Ukraine - Recruiting
Effects of Oncological Treatment During Pregnancy on Mother and Child
This study looks at how cancer and its treatments during pregnancy affect mums and their babies. Researchers want to see if babies exposed to treatments like chemotherapy develop normally, and they'll also track the mothers' health.
CancerPregnancyUkraine - RecruitingPHASE3
C-Forward: Efficacy and Safety of BEM/RZR vs SOF/VEL in Subjects With Chronic HCV
This study compares two treatments, BEM/RZR and SOF/VEL, for chronic hepatitis C in adults. It's looking to see how well they work and if they are safe. It’s for people who haven't had these types of treatments before and usually have mild or no liver damage.
HEPATITIS C VIRUS CHRONIC INFECTIONHepatitis C, ChronicHepatitis C Virus InfectionHepatitis CUkraine - RecruitingPHASE3
A Study of Orforglipron (LY3502970) on Cardiovascular Outcomes in Adults With Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease (ATTAIN-Outcomes)
This study looks at a new medicine called orforglipron for people with heart disease or kidney disease. We want to see if it can improve their heart health over about five years. Half the people will get the new medicine, and half will get a dummy medicine (placebo).
Atherosclerosis Cardiovascular DiseaseChronic Kidney DiseaseUkraine - Enrolling by invitationPHASE1
A Rollover Study for Continued Study Treatment and Ongoing Safety Monitoring
This study helps us understand the long-term safety of new treatments for certain cancers like leukemia and lymphoma. People who have already been in an earlier drug trial for these conditions will continue to be monitored to see how they respond over time.
Leukemia, Myeloid, AcuteLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Non-HodgkinMyelodysplastic SyndromesUkraine - Active not recruitingPHASE3
A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma
This study is looking at three new medicines for advanced melanoma, a type of skin cancer. It aims to see if combining these medicines helps people with melanoma that has spread and has a specific gene change called 'BRAF'.
MelanomaUkraine - RecruitingPHASE3
Study of OCTAPLEX in Patients With Acute Major Bleeding on DOAC Therapy With Factor Xa Inhibitor
This study is testing a medicine called OCTAPLEX for people experiencing serious bleeding while taking a specific type of blood thinner (Factor Xa inhibitor). Researchers want to see if OCTAPLEX can effectively stop the bleeding and if it's safe, comparing two different doses.
Acute Major BleedingUkraine - Active not recruitingPHASE3
A Phase III Study to Investigate the Efficacy and Safety of Baxdrostat in Combination With Dapagliflozin on CKD Progression in Participants With CKD and High Blood Pressure.
This study looks at a new drug, baxdrostat, combined with an existing one, dapagliflozin, for adults with chronic kidney disease and high blood pressure. It aims to see if this combination can slow down kidney disease progression safely.
Chronic Kidney Disease and HypertensionUkraine - RecruitingPHASE3
Efficacy and Safety of Masitinib Versus Placebo in the Treatment of ALS Patients
This study is testing a new medicine, Masitinib, for people with Motor Neurone Disease (ALS). It aims to see if Masitinib, when taken with the usual medicine Riluzole, can help slow down the disease compared to taking Riluzole with a dummy pill.
Amyotrophic Lateral SclerosisUkraine - Active not recruitingPHASE3
A Study to Evaluate the Long-Term Safety and Efficacy of Upadacitinib (ABT-494) in Participants With Ulcerative Colitis (UC)
This study looks at the long-term safety and effectiveness of a medicine called Upadacitinib for people with ulcerative colitis. It's for those who haven't fully responded to previous treatment or have completed an earlier study.
Ulcerative Colitis (UC)Ukraine - RecruitingPHASE2
A Study of TX000045 in Patients With Pulmonary Hypertension Secondary to Heart Failure With Preserved Ejection Fraction (the APEX Study)
The APEX study is looking at a new medicine called TX000045 for people with high blood pressure in their lungs caused by a certain type of heart failure. It will compare two doses of the medicine against a dummy treatment to see if it helps.
Pulmonary HypertensionHeart Failure With Preserved Ejection FractionUkraine - RecruitingPHASE3
A Study of Mavorixafor in Participants With Congenital and Acquired Primary Autoimmune and Idiopathic Chronic Neutropenic Disorders Who Are Experiencing Recurrent and/or Serious Infections
This study looks at a new medicine called Mavorixafor for people with a blood condition called neutropenia. It aims to see if the drug can help reduce infections and increase white blood cells called neutrophils, which fight infections.
NeutropeniaUkraine - Active not recruitingPHASE3
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
This study is for people who have already been taking a medicine called venetoclax for their cancer in another trial. It allows them to keep taking venetoclax if it's helping them and they're not having bad side effects, so doctors can learn more about its long-term safety.
Chronic Lymphocytic LeukemiaAcute Myeloid LeukemiaMultiple MyelomaNon-Hodgkin's LymphomaUkraine - Active not recruitingPHASE3
A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 )
This study is looking into a new medication called lanifibranor for adults with a liver condition called NASH (Nonalcoholic Steatohepatitis) and significant liver scarring (fibrosis F2 or F3). Researchers want to see if it's safe and helps improve the liver condition.
NASH - Nonalcoholic SteatohepatitisUkraine - Active not recruitingPHASE3
Filgotinib in Long-Term Extension Study of Adults With Ulcerative Colitis
This study looks at the long-term safety of a medicine called filgotinib for adults with ulcerative colitis. It's for people who have already been in another filgotinib study. The main goal is to see if taking filgotinib over a longer time is safe.
Ulcerative ColitisUkraine - Active not recruitingPHASE3
Study to Continue Treatment With Darolutamide in Patients Who Have Been Participating in Previous Darolutamide Studies Supported by Bayer
This study is for men with cancer who are already taking darolutamide in another Bayer study and are doing well. It lets them keep taking the same medicine at the same dose, continuing their treatment journey under medical supervision.
CancerUkraine - Active not recruitingPHASE4
Stopping Aminosalicylate Therapy in Inactive Crohn's Disease
This study looks at whether people with Crohn's disease in remission can safely stop taking a common medicine called 5-ASA. It compares stopping the medicine with continuing it to see if symptoms stay away for at least two years.
Crohn DiseaseRemissionUkraine - RecruitingPHASE2
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
This study is looking at a new medicine called LY4268989 for adults with moderate to severe ulcerative colitis (UC). It aims to see if the medicine is safe and helps improve symptoms compared to a dummy pill. It's a pill taken by mouth.
Ulcerative Colitis (UC)Ulcerative Colitis, Active ModerateUlcerative Colitis, Active SevereUkraine - RecruitingPHASE3
A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)
This study looks at new medicines, retatrutide and tirzepatide, for adults with a type of fatty liver disease called MASLD. It aims to see if these drugs can help prevent serious liver problems. Some participants will receive a dummy drug (placebo) to compare.
Metabolic Dysfunction-Associated Steatotic Liver DiseaseUkraine - Active not recruitingPHASE2
A Study to Evaluate Tobevibart+Elebsiran Versus Bulevirtide in Chronic HDV Infection
This study is testing new medicines, Tobevibart and Elebsiran, against an existing treatment, Bulevirtide. It's for people in the UK who have long-lasting hepatitis delta virus (HDV) infection to see which treatment works best to control the virus and improve liver health.
Viral HepatitisUkraine - RecruitingPHASE3
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012)
This study looks at a new drug, calderasib, for advanced bowel cancer with a specific genetic change (KRAS G12C). Researchers want to see if adding calderasib to standard treatments helps people live longer without their cancer growing.
Colon AdenocarcinomaRectal AdenocarcinomaUkraine - RecruitingPHASE3
A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004/KANDLELIT-004)
This study is testing a new combination of two medicines, calderasib and pembrolizumab, for a specific type of lung cancer. We want to see if this combination works better than current treatments for people with advanced non-small cell lung cancer that has a particular genetic change.
Non-small Cell Lung CancerUkraine - RecruitingPHASE2, PHASE3
A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)
This study is testing a new medicine, zilovertamab vedotin (ZV), combined with standard treatments for a type of lymphoma called diffuse large B-cell lymphoma (DLBCL). It's for people whose lymphoma has come back or hasn't responded to previous treatments.
DLBCLDiffuse Large B-Cell LymphomaUkraine - RecruitingPHASE3
A Clinical Study of Molnupiravir to Prevent Severe Illness From Coronavirus Disease 2019 (COVID-19) in People Who Are High Risk (MK-4482-023)
This study is testing a new medicine, Molnupiravir, to see if it can stop people at high risk of severe COVID-19 from becoming very ill. It's for people who can't take other COVID-19 treatments. We want to find out if it works better than a dummy treatment.
Coronavirus Disease (COVID-19)Ukraine - RecruitingPHASE3
A Clinical Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) in People With Breast Cancer (MK-2870-032)
This study looks for better ways to treat early-stage, high-risk breast cancer. It tests a new targeted therapy, sacituzumab tirumotecan, with other standard treatments to see if it reduces cancer and helps people live longer without the cancer returning.
Breast NeoplasmsTriple Negative Breast NeoplasmsHR Low-Positive/HER2-Negative Breast NeoplasmsUkraine - Active not recruitingPHASE3
A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012)
This study is testing new combinations of medicines for advanced kidney cancer (renal cell carcinoma). Its aim is to see if these new combinations work better and are safe compared to a standard treatment, for people who haven't had treatment for their advanced cancer before.
Carcinoma, Renal CellUkraine - Active not recruitingPHASE3
Study to Evaluate the Efficacy, Safety and Tolerability of IMU-838 in Patients With Relapsing Multiple Sclerosis
This study is testing a new tablet, IMU-838, for people aged 18-55 with a type of multiple sclerosis (MS) called relapsing MS. It wants to see how well it works, if it's safe, and if people can tolerate it compared to a dummy tablet.
Multiple Sclerosis, Relapsing-RemittingUkraine - RecruitingPHASE3
A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or Without Mixed Features, in Participants With Bipolar-I Disorder Taking Lithium, Valproate, or Lamotrigine
This study is looking into a new medication called KarXT to help people aged 18-65 with Bipolar-I disorder who are having a manic episode. It wants to see if KarXT, when added to current treatments like lithium, valproate, or lamotrigine, is safe and effective.
ManiaBipolar DisorderUkraine - Active not recruitingPHASE3
A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL
This study is looking at a new medicine called acalabrutinib. We want to see if adding it to standard treatment (bendamustine and rituximab, or BR) works better than standard treatment alone for people with a type of blood cancer called mantle cell lymphoma that hasn't been treated before.
Lymphoma, Mantle CellUkraine